BioSpace News Archive

AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on discovering and developing precision oncology therapeutics, announced today that the first patient has been dosed in its Phase 2 clinical trial evaluating AUM001 for the treatment of metastatic colorectal cancer (MSS CRC).

Day One Biopharmaceuticals announced management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14 at 11:20 a.m. PT.

IMUNON, Inc.(NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., the company’s Executive Vice President and Chief Science Officer, presented new PlaCCine preclinical data at the 2023 Viruses and Cells – Gordon Research Conference in Barcelona.

Larkspur Biosciences announced that they will be participating in the 2023 BIO International Convention being held June 5-8 at the Boston Convention & Exhibit Center, Boston, MA.

Morphogenesis, Inc. (“Morphogenesis”) and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.

Inmagene Biopharmaceuticals today announced that management has been invited to participate in the Jefferies Healthcare Conference, which will be held in New York from June 7-9, 2023.

Catalyst Pharmaceuticals, Inc. today announced the appointment of Ms. Tamar Thompson to the Company’s Board of Directors (“Board”), effective on May 25, 2023.

Harmony Biosciences Holdings, Inc. today announced that Harmony’s management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on Tuesday, June 13, 2023, at 2:00 p.m. PT/ 5:00 p.m. ET.

Rain Oncology Inc., a clinical stage company developing precision oncology therapeutics announced an update to its clinical strategy for milademetan, its small molecule inhibitor of the MDM2-p53 complex, to optimize Company resources.

A2 Biotherapeutics, Inc. today announced the first patient has been dosed in the Phase 1 clinical trial of A2B530.